The Latest Breaking News from Novavax

Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years. The authorization is a global first approval in adolescents for the vaccine manufactured and marketed in India by the Serum Institute of India under the brand name Covovax. Novavax said…

Here's a roundup of top developments in the biotech space over the last 24 hours.

A whale with a lot of money to spend has taken a noticeably bearish stance on Novavax. Looking at options history for Novavax (NASDAQ:NVAX) we detected 14 strange trades.

Pfizer Inc. (NYSE: PFE) and Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 4.3% at $52.42 and 9.6% at $80.05 respectively. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

France has begun using Novavax, a non-mRNA vaccine, to try and sway the unvaccinated as the number of Covid infections slightly increases raising concerns a sixth wave could be around the corner. But take up is slow.

The Therapeutic Goods Administration has opened the door to Novavax applying in April to register its COVID-19 vaccine for children 12 and older.

Moderna, Inc (NASDAQ: MRNA) and Novavax, Inc (NASDAQ: NVAX) were trading up over 10% and 8%, respectively, at one point on Wednesday, boosted by the S&P 500’s almost 2.6% intraday gain.

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 10.65% on an annualized basis.

Benzinga Pro data, Novavax (NASDAQ:NVAX) reported Q4 sales of $222.20 million. Earnings fell to a loss of $846.28 million, resulting in a 162.47% decrease from last quarter.